Novaterra

Europe, time to #build again. Back to factories and labs. We must immediately focus on manufacturing, biotech, defense, and space and create global champions of defensible technology.

Today we announce we gained control of Catalisi, a private community of angel investors with over 350 active investors and 7 deals done in the last year alone. www.novaterra.io/catalisi When we ideated Novaterra, our vision was to create more than just a financial firm: we set out to build a movement of individuals dedicated to directing capital toward exponential technologies and groundbreaking science. By joining Catalisi:   • You gain access to the same opportunities Novaterra funds directly.  • You become part of an exclusive community of like-minded individuals committed to backing companies with an exponential impact.  • You receive the same top-notch deal flow typically reserved for institutional investors at no additional costs. This community is for those who believe that progress demands action and, most importantly, that every small contribution counts. Check the website for more. Time to #build, together!

🏴☠️🏴☠️🏴☠️ We are proud to introduce Biocentis, a company we partnered with earlier this year, now part of our portfolio. A biotech spin-off from Imperial College London, Biocentis is developing sustainable insect control solutions aimed at tackling major global challenges in agriculture and public health. Their precision genetic technology targets harmful insect populations without impacting other species or the environment, aligning with our commitment to improving our Planet's health with scientific innovation. Congratulations, and best of luck to CEO Giorgio Rocca and the whole team Andrew Hammond Kevin Gorman Andrea Crisanti! [Link to the investment thesis in the comments]

🏴☠️🏴☠️🏴☠️ We are pleased to announce we acquired a minority interest in Modulate Bio, a Harvard University spin-out advancing novel treatments for epilepsy, tremors, and other neurological disorders. We will create next-gen therapies that provide efficacy without the side effects common to other neuro drugs. The company is advancing small molecule therapies for epilepsy and essential tremor, and the proprietary algorithm helps create significant upside to develop further medicines across anxiety, depression, PTSD, and other movement disorders. Congratulations, and best of luck to CEO Andrew Thomson, CSO Dario Doller, and the entire team! [Link to the investment thesis in the comments]

We’re excited to share that Bio4Dreams and Novaterra are joining forces to build and accelerate the next wave of #LifeScience companies! To advance our mission of driving innovation that transforms lives — from discovering cures for the incurable to extending healthier lifespans — we are partnering with Bio4Dreams, a leading incubator dedicated to early-stage companies in life sciences. With their extensive expertise, strong network, and proven track record of nurturing groundbreaking ideas, Bio4Dreams is the perfect partner as we work together toward our shared vision. Learn more at: https://lnkd.in/ewY6A6-3

Introducing Novaterra's Planet Health Investment Focus We are glad to share our second (and last) key focus of our investment thesis at Novaterra, #PlanetHealth: a portfolio of companies dedicated to preserving the Earth's ecosystems, mitigating climate change, and ensuring sustainable food and energy systems. Our commitment to leaving a mark drives us to invest in solutions that address the most pressing environmental challenges. We aim to channel capital into ventures that sustain our planet for future generations. We are focusing on three crucial areas: #ClimateChange: our investments aim to reduce global carbon emissions, protect biodiversity, and advance technologies to combat natural disasters and rising sea levels. #EnergyTransition: we support the shift towards renewable energy, promoting innovations in hydrogen power, battery storage, and next-generation nuclear technology to ensure a cleaner and more sustainable future. #AgriFoodTech: by investing in sustainable agriculture and food technologies, we strive to enhance food security, reduce waste, and develop alternative protein sources to feed a growing global population. Visit our website to learn more about how we are working to protect our planet: https://lnkd.in/eVv4dqgk #Sustainability #Innovation #ClimateAction #Novaterra

Check out this interview about the incredible work being done at Ilios Therapeutics, one of our portfolio companies. In the latest episode of "The Dish," Luca Giani dives into how asking one simple question led to the creation of Ilios Therapeutics, a company that's making waves in the fight against neurodegenerative diseases. Their innovative approach, including the development of first-in-class small molecules to combat protein misfolding, oxidative stress, and neuro-inflammation, has already garnered attention from leading initiatives. Full link to the episode: https://lnkd.in/eKDtwVZ6

Introducing Novaterra's Human Preservation Investment Focus. At Novaterra, we are committed to investing in science and technology to address the most critical challenges of our time. Our aim is to redirect traditional capital to sustain impactful innovation. One of the two investment focuses of our thesis is #HumanPreservation: a portfolio of companies committed to improving the human condition, by curing incurable diseases, making life longer and healthier, and increasing the chances of surviving. As such, we will invest in three key areas: #LifeSciences: Our life sciences focus spans the increase of quality of life through research, development, clinical trials, and ultimately new drug manufacturing. #HealthTech: Innovation in this field leverages technology to transform healthcare delivery by improving accessibility, quality, and efficiency. #SpaceExploration: This industry has experienced remarkable innovation, turning it into one that can deeply impact humanity, by making life multi-planetary. Visit our website to learn more about how we intend to contribute to Humanity: https://lnkd.in/e7zmVwmQ #HealthTech #Novaterra

Doors open at Novaterra! In our ideal world, it shouldn’t be founders chasing venture capital; rather, investors should chase groundbreaking founders. As a Founder, you aim to leave a mark. That mark should be left on the value added by your product, which should always be put first. As such, we value entrepreneurs who concentrate their efforts on their product breakthroughs and customers rather than spending their limited time seeking funding. To make this happen we want to introduce an open door policy at Novaterra from the beginning on. Our office hours are the opportunity for Founders to get uncomplicated, direct feedback on questions they have, directly from our Partners & Friends. This June, our Partners Tarek Fahmy (prev. SVP of Engineering at Wish) and Oliver Lesche (serial Founder&Investor in IT) open their doors for direct meetings. If your company falls within the scope of Novaterra and you perceive value in the expertise Tarek and Oliver bring to the table, then register here (https://tally.so/r/wdYj6y). We will follow up with you on the next steps to meet.

I am happy, glad, thrilled, delighted - and many other considerable adjectives - to announce that after almost three years at Startupgym Studio (with many failures and a couple of successes), I am still here… just to start all over again! Today, Novaterra is officially born 🏴☠️ In the last months, I took the responsibility to guide the company into this new shape: my life goal is to try to prove we can make good use of capital, without harming society, instead making it better by tackling pressing needs and unsolved challenges. To do this, traditional investment models are clearly not sufficient anymore. Goodbye Studio, welcome Investments. Goodbye Startups, welcome Finance. Goodbye Software, welcome Science. Now, it’s my turn and I can’t wait to build. As always, without bullshit proclaims, but only with a natural hunger to win. https://novaterra.io/ #buildingtomorrow #novaterra